TRML241220P15000
- 0.60
- 0.000.00%
Tourmaline Bio Newsroom
Piper Sandler Maintains Tourmaline Bio(TRML.US) With Buy Rating, Maintains Target Price $65
Analysts' Top Healthcare Picks: Neumora Therapeutics, Inc. (NMRA), Tourmaline Bio (TRML)
H.C. Wainwright Maintains Tourmaline Bio(TRML.US) With Buy Rating, Raises Target Price to $49
Tourmaline Bio's Promising Clinical Developments and Financial Stability Underpin Buy Rating
Guggenheim Maintains Tourmaline Bio(TRML.US) With Buy Rating
Truist Financial Maintains Tourmaline Bio(TRML.US) With Buy Rating
Truist Financial Maintains Tourmaline Bio(TRML.US) With Buy Rating
Piper Sandler Maintains Tourmaline Bio(TRML.US) With Buy Rating, Maintains Target Price $65
Cantor Fitzgerald Initiates Tourmaline Bio(TRML.US) With Buy Rating
Guggenheim Maintains Tourmaline Bio(TRML.US) With Buy Rating
Truist Financial Maintains Tourmaline Bio(TRML.US) With Buy Rating
Truist Financial Maintains Tourmaline Bio(TRML.US) With Buy Rating
Piper Sandler Maintains Tourmaline Bio(TRML.US) With Buy Rating, Maintains Target Price $65
Tourmaline Bio (TRML) Receives a Buy From Piper Sandler
Analysts Offer Insights on Healthcare Companies: Tourmaline Bio (TRML), Amicus (FOLD) and Kura Oncology (KURA)
Truist Financial Maintains Tourmaline Bio(TRML.US) With Buy Rating, Announces Target Price $15
Tourmaline Bio Analyst Ratings
Buy Rating Affirmed for Tourmaline Bio Amid Promising Clinical Trials and Strong Market Potential
Truist Financial Reaffirms Their Buy Rating on Tourmaline Bio (TRML)
Tourmaline Bio Analyst Ratings